Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022 - Takeaways - MDSpire

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  • By

  • John A. Snowden

  • Isabel Sánchez-Ortega

  • Selim Corbacioglu

  • Grzegorz W. Basak

  • Christian Chabannon

  • Rafael de la Camara

  • Harry Dolstra

  • Rafael F. Duarte

  • Bertram Glass

  • Raffaella Greco

  • Arjan C. Lankester

  • Mohamad Mohty

  • Bénédicte Neven

  • Régis Peffault de Latour

  • Paolo Pedrazzoli

  • Zinaida Peric

  • Ibrahim Yakoub-Agha

  • Anna Sureda

  • Nicolaus Kröger

  • May 19, 2022

  • 0 min

Share

  • 1

    The 2022 EBMT report provides guidance on haematopoietic cell transplantation (HCT) based on clinical trials and expert opinions.

  • 2

    HCT recommendations consider disease status, treatment-related mortality, patient co-morbidities, and quality of life.

  • 3

    COVID-19 has impacted HCT activity, necessitating prioritization and adjustments in treatment protocols across regions.

  • 4

    HCT donor types include autologous, syngeneic, and allogeneic, with evolving practices for mismatched and haploidentical donors.

  • 5

    EBMT classifies transplant indications into four categories, reflecting varying levels of evidence and recommendations for procedures.

Original Source(s)

Related Content